Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2015, Article ID 138573, 8 pages
http://dx.doi.org/10.1155/2015/138573
Research Article

Profiling of Somatic Mutations in Phaeochromocytoma and Paraganglioma by Targeted Next Generation Sequencing Analysis

1Department of Medical Genetics, University of Cambridge, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK
2Cambridge NIHR Biomedical Research Centre, Addenbrooke’s Hospital, Cambridge CB2 0QQ, UK
3Centre for Rare Diseases and Personalised Medicine, University of Birmingham, Birmingham B15 2TT, UK
4Queen Elizabeth Hospital, Queen Elizabeth Medical Centre, Birmingham B15 2TH, UK
5Department of Otology & Skull Base Surgery, Gruppo Otologico, Via Antonio Emmanueli 42, 29121 Piacenza, Italy
6Department of Medical, Oral and Biotechnological Sciences, G. d’Annunzio University, Via dei Vestini 1, 66100 Chieti, Italy
7Department of Urology, Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawa Ward, Yokohama, Kanagawa 236-0004, Japan
8Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
9ISCIII Center for Biomedical Research on Rare Diseases (CIBERER), Madrid, Spain
10Section of Preventive Medicine, Department of Nephrology, Albert Ludwigs University of Freiburg, Hugstetter Strasse 55, 79106 Freiburg, Germany
11Department of Clinical Genetics, Birmingham Women’s Hospital, Birmingham B15 2TG, UK

Received 27 June 2014; Revised 23 August 2014; Accepted 26 August 2014

Academic Editor: Claudio Letizia

Copyright © 2015 Andrea Luchetti et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Jafri and E. R. Maher, “The genetics of phaeochromocytoma: using clinical features to guide genetic testing,” European Journal of Endocrinology, vol. 166, no. 2, pp. 151–158, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. A.-P. Gimenez-Roqueplo, P. L. Dahia, and M. Robledo, “An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes,” Hormone and Metabolic Research, vol. 44, no. 5, pp. 328–333, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. H. P. Neumann, B. Bausch, S. R. McWhinney et al., “Germ-line mutations in nonsyndromic pheochromocytoma,” The New England Journal of Medicine, vol. 346, no. 19, pp. 1459–1466, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. N. Burnichon, L. Vescovo, L. Amar et al., “Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma,” Human Molecular Genetics, vol. 20, no. 20, pp. 3974–3985, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. N. Burnichon, A. Buffet, B. Parfait et al., “Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma,” Human Molecular Genetics, vol. 21, no. 26, pp. 5397–5405, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. Z. Zhuang, C. Yang, F. Lorenzo et al., “Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia,” The New England Journal of Medicine, vol. 367, no. 10, pp. 922–930, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. I. Comino-Méndez, A. A. de Cubas, C. Bernal et al., “Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis,” Human Molecular Genetics, vol. 22, no. 11, pp. 2169–2176, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. E. Rattenberry, L. Vialard, A. Yeung et al., “A comprehensive next generation sequencing-based genetic testing strategy to improve diagnosis of inherited pheochromocytoma and paraganglioma,” Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 7, pp. E1248–E1256, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. B. E. Baysal, R. E. Ferrell, J. E. Willett-Brozick et al., “Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma,” Science, vol. 287, no. 5454, pp. 848–851, 2000. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Niemann and U. Müller, “Mutations in SDHC cause autosomal dominant paraganglioma, type 3,” Nature Genetics, vol. 26, no. 3, pp. 268–270, 2000. View at Publisher · View at Google Scholar · View at Scopus
  11. D. Astuti, F. Latif, A. Dallol et al., “Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma,” The American Journal of Human Genetics, vol. 69, no. 1, pp. 49–54, 2001. View at Publisher · View at Google Scholar · View at Scopus
  12. N. Burnichon, J.-J. Brière, R. Libé et al., “SDHA is a tumor suppressor gene causing paraganglioma,” Human Molecular Genetics, vol. 19, no. 15, pp. 3011–3020, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. G. Eisenhofer, T.-T. Huynh, K. Pacak et al., “Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome,” Endocrine-Related Cancer, vol. 11, no. 4, pp. 897–911, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. E. López-Jiménez, G. Gómez-López, L. J. Leandro-García et al., “Research resource: transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas,” Molecular Endocrinology, vol. 24, no. 12, pp. 2382–2391, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. P. L. Dahia, K. N. Ross, M. E. Wright et al., “AHIF1α regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas,” PLoS Genetics, vol. 1, pp. 172–180, 2005. View at Publisher · View at Google Scholar
  16. A. Vicha, Z. Musil, and K. Pacak, “Genetics of pheochromocytoma and paraganglioma syndromes: new advances and future treatment options,” Current Opinion in Endocrinology, Diabetes and Obesity, vol. 20, no. 3, pp. 186–191, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. P. L. M. Dahia, K. Hao, J. Rogus et al., “Novel pheochromocytoma susceptibility loci identified by integrative genomics,” Cancer Research, vol. 65, no. 21, pp. 9651–9658, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. J. Favier and A.-P. Gimenez-Roqueplo, “Pheochromocytomas: the (pseudo)-hypoxia hypothesis,” Best Practice and Research: Clinical Endocrinology and Metabolism, vol. 24, no. 6, pp. 957–968, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Crona, A. Delgado Verdugo, R. Maharjan et al., “Somatic mutations in H-RAS in sporadic pheochromocytoma and paraganglioma identified by exome sequencing,” Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 7, pp. E1266–E1271, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. L. Oudijk, R. Ronald, R. R. de Krijger et al., “H-RAS mutations are restricted to sporadic pheochromocytomas lacking specific clinical or pathological features: data from a multi-institutional series,” The Journal of Clinical Endocrinology and Metabolism, vol. 99, no. 7, pp. E1376–E1380, 2014. View at Publisher · View at Google Scholar
  21. J. S. Ross and M. Cronin, “Whole cancer genome sequencing by next-generation methods,” American Journal of Clinical Pathology, vol. 136, no. 4, pp. 527–539, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Blanes, J. J. Sanchez-Carrillo, and S. J. Diaz-Cano, “Topographic molecular profile of pheochromocytomas: role of somatic down-regulation of mismatch repair,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 3, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Cascon, S. Ruiz-Llorente, M. F. Fraga et al., “Genetic and epigenetic profile of sporadic pheochromocytomas,” Journal of Medical Genetics, vol. 41, no. 3, article e30, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Sandgren, R. Andersson, A. Rada-Iglesias et al., “Integrative epigenomic and genomic analysis of malignant pheochromocytoma,” Experimental and Molecular Medicine, vol. 42, no. 7, pp. 484–502, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Hering, M. Guratowska, P. Bucsky et al., “Characteristic genomic imbalances in pediatric pheochromocytoma,” Genes, Chromosomes and Cancer, vol. 45, no. 6, pp. 602–607, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. H. Dannenberg, E. J. M. Speel, J. Zhao et al., “Losses of chromosomes 1p and 3q are early genetic events in the development of sporadic pheochromocytomas,” American Journal of Pathology, vol. 157, no. 2, pp. 353–359, 2000. View at Publisher · View at Google Scholar · View at Scopus
  27. E. Edstrom, E. Mahlamaki, B. Nord et al., “Comparative genomic hybridization reveals frequent losses of chromosomes 1p and 3q in pheochromocytomas and abdominal paragangliomas, suggesting a common genetic etiology,” The American Journal of Pathology, vol. 156, no. 2, pp. 651–659, 2000. View at Publisher · View at Google Scholar · View at Scopus
  28. F. H. van Naderveen, E. Korpershoek, R. J. deLeeuw et al., “Array-comparative genomic hybridization in sporadic benign pheochromocytomas,” Endocrine-Related Cancer, vol. 16, no. 2, pp. 505–513, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Sandgren, T. Diaz de Stahl, R. Andersson et al., “Recurrent genomic alterations in benign and malignant pheochromocytomas and paragangliomas revealed by whole-genome array comparative genomic hybridization analysis,” Endocrine-Related Cancer, vol. 17, no. 3, pp. 561–579, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. D. Astuti, F. Douglas, T. W. J. Lennard et al., “Germline SDHD mutation in familial phaeochromocytoma,” The Lancet, vol. 357, no. 9263, pp. 1181–1182, 2001. View at Publisher · View at Google Scholar · View at Scopus
  31. C. D. E. Margetts, D. Astuti, D. C. Gentle et al., “Epigenetic analysis of HIC1, CASP8, FLIP, TSP1, DCR1, DCR2, DR4, DR5, KvDMR1, H19 and preferential 11p15.5 maternal-allele loss in von Hippel-Lindau and sporadic phaeochromocytomas,” Endocrine-Related Cancer, vol. 12, no. 1, pp. 161–172, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. J. Geli, N. Kiss, M. Karimi et al., “Global and regional CpG methylation in pheochromocytomas and abdominal paragangliomas: association to malignant behavior,” Clinical Cancer Research, vol. 14, no. 9, pp. 2551–2559, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. P. L. M. Dahia, “Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity,” Nature Reviews Cancer, vol. 14, no. 2, pp. 108–119, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. Y. Aoki, T. Niihori, H. Kawame et al., “Germline mutations in HRAS proto-oncogene cause Costello syndrome,” Nature Genetics, vol. 37, no. 10, pp. 1038–1040, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. S. M. Kumar, J. Dai, S. Li et al., “Human skin neural crest progenitor cells are susceptible to BRAF V600E-induced transformation,” Oncogene, vol. 33, no. 7, pp. 832–841, 2014. View at Publisher · View at Google Scholar · View at Scopus
  36. K. T. Flaherty, I. Puzanov, K. B. Kim et al., “Inhibition of mutated, activated BRAF in metastatic melanoma,” The New England Journal of Medicine, vol. 363, no. 9, pp. 809–819, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. D. N. Hayes, A. S. Lucas, T. Tanvetyanon et al., “Phase II efficacy and pharmacogenomic study of selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements,” Clinical Cancer Research, vol. 18, no. 7, pp. 2056–2065, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. D. A. Liebner and M. H. Shah, “Thyroid cancer: pathogenesis and targeted therapy,” Therapeutic Advances in Endocrinology and Metabolism, vol. 2, no. 5, pp. 173–195, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Xing, “BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications,” Endocrine Reviews, vol. 28, no. 7, pp. 742–762, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. S. Seitz, K. Poppe, J. Fischer et al., “Detailed deletion mapping in sporadic breast cancer at chromosomal region 17p13 distal to theTP53 gene: association with clinicopathological parameters,” The Journal of Pathology, vol. 194, pp. 318–326, 2001. View at Publisher · View at Google Scholar
  41. M. Risio, L. Casorzo, L. Chiecchio, G. de Rosa, and F. P. Rossini, “Deletions of 17p are associated with transition from early to advanced colorectal cancer,” Cancer Genetics and Cytogenetics, vol. 147, no. 1, pp. 44–49, 2003. View at Publisher · View at Google Scholar · View at Scopus
  42. X. Y. Guan, J. S. Sham, L. S. Tai, Y. Fang, H. Li, and Q. Liang, “Evidence for another tumor suppressor gene at 17p13.3 distal to TP53 in hepatocellular carcinoma,” Cancer Genetics and Cytogenetics, vol. 140, no. 1, pp. 45–48, 2003. View at Publisher · View at Google Scholar · View at Scopus
  43. B.-J. Petri, E.-J. M. Speel, E. Korpershoek et al., “Frequent loss of 17p, but no p53 mutations or protein overexpression in benign and malignant pheochromocytomas,” Modern Pathology, vol. 21, no. 4, pp. 407–413, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. T. Yoshimoto, M. Naruse, Z. Zeng et al., “The relatively high frequency of p53 gene mutations in multiple and malignant phaeochromocytomas,” Journal of Endocrinology, vol. 159, no. 2, pp. 247–255, 1998. View at Publisher · View at Google Scholar · View at Scopus
  45. K. K. Herfarth, M. R. Wick, H. N. Marshall, E. Gartner, S. Lum, and J. F. Moley, “Absence of TP53 alterations in pheochromocytomas and medullary thyroid carcinomas,” Genes, Chromosomes and Cancer, vol. 20, no. 1, pp. 24–29, 1997. View at Google Scholar
  46. B. C. Figueiredo, R. Sandrini, G. P. Zambetti et al., “Penetrance of adrenocortical tumours associated with the germline TP53 R337H mutation,” Journal of Medical Genetics, vol. 43, no. 1, pp. 91–96, 2006. View at Publisher · View at Google Scholar · View at Scopus
  47. E. Michalkiewicz, R. Sandrini, B. Figueiredo et al., “Clinical and outcome characteristics of children with adrenocortical tumors: a report from the international pediatric adrenocortical tumor registry,” Journal of Clinical Oncology, vol. 22, no. 5, pp. 838–845, 2004. View at Publisher · View at Google Scholar · View at Scopus
  48. M. I. W. Achatz, M. Olivier, F. L. Calvez et al., “The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families,” Cancer Letters, vol. 245, no. 1-2, pp. 96–102, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. J. G. Assumpção, A. L. Seidinger, M. J. Mastellaro et al., “Association of the germline TP53 R337H mutation with breast cancer in Southern Brazil,” BMC Cancer, vol. 8, article 357, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. E. I. Palmero, L. Schuler-Faccini, M. Caleffi et al., “Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil,” Cancer Letters, vol. 261, no. 1, pp. 21–25, 2008. View at Publisher · View at Google Scholar · View at Scopus
  51. G. Custodio, G. R. Taques, B. C. Figueiredo et al., “Increased incidence of choroid plexus carcinoma due to the germline TP53 R337H mutation in southern Brazil,” PLoS ONE, vol. 6, no. 3, Article ID e18015, 2011. View at Publisher · View at Google Scholar · View at Scopus
  52. A. L. Seidinger, M. J. Mastellaro, F. Paschoal Fortes et al., “Association of the highly prevalent TP53 R337H mutation with pediatric choroid plexus carcinoma and osteosarcoma in Southeast Brazil,” Cancer, vol. 117, no. 10, pp. 2228–2235, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. H. Yang, D. Ye, K.-L. Guan, and Y. Xiong, “IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives,” Clinical Cancer Research, vol. 18, no. 20, pp. 5562–5571, 2012. View at Publisher · View at Google Scholar · View at Scopus
  54. J. Gaal, N. Burnichon, E. Korpershoek et al., “Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas,” The Journal of Clinical Endocrinology & Metabolism, vol. 95, no. 3, pp. 1274–1278, 2010. View at Publisher · View at Google Scholar · View at Scopus
  55. A.-P. Gimenez-Roqueplo, J. Favier, P. Rustin et al., “Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas,” Cancer Research, vol. 63, no. 17, pp. 5615–5621, 2003. View at Google Scholar · View at Scopus
  56. F. M. Brouwers, G. Eisenhofer, J. J. Tao et al., “High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 11, pp. 4505–4509, 2006. View at Publisher · View at Google Scholar · View at Scopus
  57. C. J. Ricketts, J. R. Forman, E. Rattenberry et al., “Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD,” Human Mutation, vol. 31, no. 1, pp. 41–51, 2010. View at Publisher · View at Google Scholar · View at Scopus